# US 2024/0002807 A1 · Differentiation of human embryonic stem cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0002807 A1
- Document ID: US20240002807A1
- Status: Published application
- Kind: A1
- Application number: 18/210,821
- Filed: 2023-06-16
- Published: 2024-01-04
- Earliest claimed: 2006-04-28
- Assignees: Janssen Biotech, Inc.
- Applicants: Janssen Biotech, Inc.
- Inventors: Alireza Rezania; Jean Xu
- Web page: https://patentgrep.com/patent/US20240002807A1

## CPC

- C12N 5/0676: {Pancreatic cells}
- A61K 35/39: Pancreas; Islets of Langerhans (Langerhans cells of epidermis A61K35/36)
- C12N 5/067: {Hepatocytes}
- C12N 2501/115: Basic fibroblast growth factor (bFGF, FGF-2)
- C12N 2501/119: Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
- C12N 2501/16: Activin; Inhibin; Mullerian inhibiting substance
- C12N 2501/385: of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
- C12N 2501/415: Wnt; Frizzeled
- C12N 2501/42: Notch; Delta; Jagged; Serrate
- C12N 2501/70: Enzymes
- C12N 2501/727: Kinases (EC 2.7.)
- C12N 2506/02: from embryonic cells
- C12N 2533/90: Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides methods to promote the differentiation of pluripotent stem cells. In particular, the present invention provides an improved method for the formation of pancreatic endoderm, pancreatic hormone expressing cells and pancreatic hormone secreting cells. The present invention also provides methods to promote the differentiation of pluripotent stem cells without the use of a feeder cell layer.

## Claims

### Claim 1

A method for producing pancreatic endoderm lineage cells expressing NKX2.2 and PDX1, comprising:
obtaining definitive endoderm cells; and
differentiating the definitive endoderm cells with a medium comprising a transforming growth factor (TGF)-β receptor agonist, retinoic acid or a retinoic acid analog, and a fibroblast growth factor (FGF),
thereby producing pancreatic endoderm lineage cells expressing NKX2.2 and PDX1.

### Claim 2 (depends on 1)

The method of claim 1, wherein the TGF-β receptor agonist is activin A.

### Claim 3 (depends on 2)

The method of claim 2, wherein the medium comprises 100 ng/mL activin A.

### Claim 4 (depends on 1)

The method of claim 1, wherein the medium comprises 1 μM retinoic acid

### Claim 5 (depends on 1)

The method of claim 1, wherein the FGF is FGF-2, FGF4 or FGF-10.

### Claim 6 (depends on 5)

The method of claim 5, wherein the FGF is FGF-2.

### Claim 7 (depends on 6)

The method of claim 6, wherein the medium comprises 50 ng/mL FGF-2.

### Claim 8 (depends on 1)

The method of claim 1, wherein obtaining definitive endoderm cells comprises differentiating pluripotent stem cells into definitive endoderm cells by treating the pluripotent stem cells with a TGF-β receptor agonist.

### Claim 9 (depends on 8)

The method of claim 8, wherein the TGF-β receptor agonist is activin A.

### Claim 10

A composition comprising an isolated human pancreatic endoderm lineage cell population expressing NKX2.2 and PDX1, a transforming growth factor (TGF)-β receptor agonist, retinoic acid and a fibroblast growth factor (FGF).

### Claim 11 (depends on 10)

The composition of claim 10, wherein the TGF-β receptor agonist is activin A.

### Claim 12 (depends on 11)

The composition of claim 11, comprising 100 ng/mL activin A.

### Claim 13 (depends on 10)

The composition of claim 10, comprising 1 μM retinoic acid

### Claim 14 (depends on 10)

The composition of claim 10, wherein the FGF is FGF-2, FGF4 or FGF-10.

### Claim 15 (depends on 14)

The composition of claim 14, wherein the FGF is FGF-2.

### Claim 16 (depends on 15)

The composition of claim 15, comprising 50 ng/mL FGF-2.
